Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD)
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
This PHASE3 trial investigates Duchenne Muscular Dystrophy and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jun 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Neurological Disorders and Stroke (NINDS)
- Newcastle University
- University Medical Center Freiburg
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .